Altretamine._Altretamine_is_a_National_Cancer_Institute-designated_group_C_antineoplastic_agent_used_in_the_treatment_of_advanced_ovarian_cancer._Altretamine_is_a_highly_lipid-soluble_drug_available_only_for_oral_administration_as_a_capsule._The_drug_is_activated_through_metabolic_oxidation_to_intermediate_methylol_derivatives_and_formaldehyde._It_is_unclear_which_metabolite_is_the_major_species_responsible_for_cytotoxicity_or_the_primary_mechanism_of_cytotoxicity._As_a_single_agent_in_the_treatment_of_ovarian_cancer,_altretamine_demonstrates_a_response_rate_similar_to_other_active_agents_in_this_disease_(21-39_percent)._The_major_utility_of_altretamine_is_in_combination_with_other_agents_such_as_cyclophosphamide,_doxorubicin,_fluorouracil,_melphalan,_and_cisplatin._However,_few_randomized_trials_have_evaluated_the_contribution_of_altretamine_in_these_multiagent_combinations._Dose-limiting_toxicities_include_gastrointestinal_(nausea,_vomiting,_anorexia),_hematologic,_and_neurotoxic_(peripheral_neurotoxicity)._The_therapeutic_role_of_altretamine_is_limited_because_of_a_toxicity_profile_similar_to_that_of_cisplatin,_one_of_the_more_active_agents_in_ovarian_cancer._Its_use_should_be_reserved_for_patients_who_are_not_candidates_for_more_standard_platinum-based_regimens.